Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 12/20 | 0.74 |
| ▸ | CCKBR | P32239 | 7/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5802825 | 0.93 | BDKRB1 (0.76) | BDKRB1CCKBR | |
| SCHEMBL3049609 | 0.85 | BDKRB1 (1.00) | BDKRB1CCKBR | |
| SCHEMBL7593167 | 0.83 | BDKRB1 (1.00) | BDKRB1CCKBR | |
| SCHEMBL1713172 | 0.81 | BDKRB1 (0.91) | BDKRB1CCKBR | |
| SCHEMBL13985117 | 0.80 | BDKRB1 (0.91) | BDKRB1CCKBR | |
| SCHEMBL7603693 | 0.73 | BDKRB1 (0.72) | BDKRB1CCKBR | |
| SCHEMBL5800119 | 0.73 | BDKRB1 (0.59) | BDKRB1CCKBR | |
| SCHEMBL7595853 | 0.71 | BDKRB1 (0.84) | BDKRB1CCKBR | |
| SCHEMBL5803119 | 0.70 | BDKRB1 (0.56) | BDKRB1CCKBR | |
| SCHEMBL7598779 | 0.70 | BDKRB1 (0.86) | BDKRB1CCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060217362-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2006-09-28 | — | — | US | claimed |
| WO-2006071775-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | ELAN PHARMACEUTICALS, INC. (US) | 2006-07-06 | — | — | WO | claimed |
| US-20060217362-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217362-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | BDKRB1, BDKRB2, NPBWR1 | BDKRB1 1/4885CCKBR 37/4885CHRM4 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.